MX2009004279A - Hidroxamatos como inhibidores de histona desacetilasa. - Google Patents

Hidroxamatos como inhibidores de histona desacetilasa.

Info

Publication number
MX2009004279A
MX2009004279A MX2009004279A MX2009004279A MX2009004279A MX 2009004279 A MX2009004279 A MX 2009004279A MX 2009004279 A MX2009004279 A MX 2009004279A MX 2009004279 A MX2009004279 A MX 2009004279A MX 2009004279 A MX2009004279 A MX 2009004279A
Authority
MX
Mexico
Prior art keywords
radical
formula
histone deacetylase
inhibitors
linker1
Prior art date
Application number
MX2009004279A
Other languages
English (en)
Inventor
Alan Hornsby Davidson
Sanjay Ratilal Patel
Alan Hastings Drummond
David Festus Charles Moffat
Alistair David Graham Donald
Andrew James Belfield
Francesca Ann Day
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of MX2009004279A publication Critical patent/MX2009004279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen compuestos de la fórmula (I), y sales, N-óxidos, hidratos y solvatos de los mismos los cuales con inhibidores de histona desacetilasa y son útiles en el tratamiento de enfermedades proliferativas de células, incluyendo cánceres: (ver fórmula (A)) en donde Q, V y W representan independientemente -N= o -C=; B es un radical divalente seleccionado de (B1), (B2), (B3), (B4, (B5) y (B6), (ver fórmulas) en donde el enlace marcado * está enlazado al anillo que contiene Q, V y W a través de -[Enlazador1]- y el enlace marcado ** está enlazado a A a través de -[Enlazador2]-; A es un sistema de anillos carbocíclico o heterocíclico mono-, bi- o tricíclico sustituido opcionalmente; -[Enlazador1]- y -[Enlazador2]- representan independientemente un enlace, o un radical enlazador divalente y R es (a) un radical de la fórmula R1R2CHNH-Y-L1-X1-(CH2)z- o (b) un radical de la fórmula R-L1-Y1-(CH2)z-.
MX2009004279A 2006-10-30 2006-10-30 Hidroxamatos como inhibidores de histona desacetilasa. MX2009004279A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2006/004034 WO2008053131A1 (en) 2006-10-30 2006-10-30 Hydroxamates as inhibitors of histone deacetylase

Publications (1)

Publication Number Publication Date
MX2009004279A true MX2009004279A (es) 2009-05-22

Family

ID=38169393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004279A MX2009004279A (es) 2006-10-30 2006-10-30 Hidroxamatos como inhibidores de histona desacetilasa.

Country Status (12)

Country Link
US (1) US8962825B2 (es)
EP (1) EP2077999B1 (es)
JP (1) JP5043120B2 (es)
KR (1) KR20090087013A (es)
CN (1) CN101553475B (es)
BR (1) BRPI0622100A2 (es)
CA (1) CA2668070A1 (es)
EA (1) EA017198B1 (es)
ES (1) ES2509342T3 (es)
IL (1) IL198263A0 (es)
MX (1) MX2009004279A (es)
WO (1) WO2008053131A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP5043120B2 (ja) 2006-10-30 2012-10-10 クロマ セラピューティクス リミテッド ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
RS56184B1 (sr) 2012-10-17 2017-11-30 Macrophage Pharma Ltd Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova so, hidrat ili solvat
ES2862126T3 (es) 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
MX2016014911A (es) 2014-05-14 2017-04-06 Univ Colorado Regents Acidos hidroxamicos heterociclicos como inhibidores de proteina desacetilasa e inhibidores dobles de proteina desacetilasa-proteina cinasa, y metodos de uso de los mismos.
EP3166603B1 (en) 2014-07-07 2020-02-12 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
WO2016126724A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
WO2017216297A1 (en) 2016-06-16 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Dosage regimen
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
CN109810108B (zh) * 2019-03-20 2021-08-06 华东理工大学 2,8-二氮杂-螺-[4,5]-癸烷类嘧啶-异羟肟酸化合物及其用途
KR20220034736A (ko) 2019-05-31 2022-03-18 비락타 서브시디어리 인크. 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법
TW202317534A (zh) 2021-06-16 2023-05-01 美商西建公司 用於治療神經退化性疾病之含羧酸吖丁啶基化合物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1099355B (it) * 1978-10-12 1985-09-18 Sclavo Inst Sieroterapeut Composizione adatta alla determinazione in cinetica del glucosio
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
CN1378450A (zh) 1999-09-08 2002-11-06 斯隆-凯特林癌症研究院 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法
EP1233958B1 (en) 1999-11-23 2011-06-29 MethylGene Inc. Inhibitors of histone deacetylase
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
ATE430567T1 (de) 2000-09-29 2009-05-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe zur behandlung von malaria
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002069947A2 (en) 2001-01-12 2002-09-12 Methylgene, Inc. Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
US20060058553A1 (en) * 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
EP1485099B1 (en) 2002-03-13 2010-07-07 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
DE60321548D1 (de) * 2002-03-13 2008-07-24 Janssen Pharmaceutica Nv Carbonylamino- derivativate als neue inhibitoren von histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
JP4606027B2 (ja) 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
WO2004013130A1 (en) 2002-08-02 2004-02-12 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
EP1562925B1 (en) 2002-11-07 2007-01-03 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
DE602004021573D1 (de) 2003-04-07 2009-07-30 Pharmacyclics Inc Hydroxamate als therapeutische mittel
WO2004092145A1 (en) 2003-04-15 2004-10-28 Pfizer Inc. Alpha substituted carboxylic acid as ppar modulators
WO2004110989A1 (en) 2003-05-14 2004-12-23 Bayer Pharmaceuticals Corporation N-hydroxy-7-(arylamino)heptanamide derivatives useful for treating hyper-proliferative disorders
CA2531661C (en) 2003-07-07 2013-03-12 Georgetown University Histone deacetylase inhibitors and methods of use thereof
EP1663201A4 (en) 2003-07-15 2009-10-28 Korea Res Inst Of Bioscience USE OF NEW 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
KR20130081319A (ko) 2003-07-29 2013-07-16 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 아미노산 프로드럭
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
WO2005013958A1 (en) 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
PL1656348T4 (pl) 2003-08-20 2007-07-31 Pharmacyclics Inc Pochodne acetylenu jako inhibitory deacetylazy histonowej
EP2201947A3 (en) 2003-08-26 2010-08-11 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
NZ545864A (en) 2003-09-22 2009-12-24 S Bio Pte Ltd Benzimidazole derivates: preparation and pharmaceutical applications
WO2005030704A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
WO2005037272A1 (en) * 2003-10-22 2005-04-28 Arpida A/S Benzimidazole derivatives and use thereof as peptide deformylase inhibitors
GB0509223D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
AU2006243000B2 (en) * 2005-05-05 2011-05-26 Macrophage Pharma Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
GB0510204D0 (en) * 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
GB0608821D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
GB0608823D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608837D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
AU2007246869B2 (en) * 2006-05-04 2012-10-18 Macrophage Pharma Limited p38 MAP kinase inhibitors
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
NZ577153A (en) * 2006-10-25 2012-02-24 Chroma Therapeutics Ltd Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
GB0621203D0 (en) * 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
JP5043120B2 (ja) 2006-10-30 2012-10-10 クロマ セラピューティクス リミテッド ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート
GB0622084D0 (en) * 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90

Also Published As

Publication number Publication date
BRPI0622100A2 (pt) 2011-12-27
US20100317678A1 (en) 2010-12-16
US8962825B2 (en) 2015-02-24
EP2077999A1 (en) 2009-07-15
EA017198B1 (ru) 2012-10-30
AU2006350475A1 (en) 2008-05-08
JP5043120B2 (ja) 2012-10-10
CA2668070A1 (en) 2008-05-08
EP2077999B1 (en) 2014-07-30
CN101553475B (zh) 2013-04-24
KR20090087013A (ko) 2009-08-14
IL198263A0 (en) 2009-12-24
EA200900617A1 (ru) 2010-04-30
WO2008053131A1 (en) 2008-05-08
ES2509342T3 (es) 2014-10-17
CN101553475A (zh) 2009-10-07
JP2010508255A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
MX2009004279A (es) Hidroxamatos como inhibidores de histona desacetilasa.
MX2007013066A (es) Inhibidores de deacetilasa histona.
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
IL199972A (en) Tricyclic compounds and their use as modulators of glucocorticoid receptor
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
JO2885B1 (en) Protein kinase inhibitors
WO2010031184A8 (en) Azaindole derivatives as crth2 receptor antagonists
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
MY152062A (en) Indole derivatives as crth2 receptor antagonists
ATE468328T1 (de) Multimere von pyrimidinonderivaten und deren verwendung als inhibitoren der humanen neutrophilelastase
TW200701982A (en) Novel use of peptide compounds for treating pain in trigeminal neuralgia
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
MX2009008286A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
HK1142775A1 (en) Therapeutic pyrazoloquinoline derivatives
TW200720262A (en) Novel compounds ii
MX2009005366A (es) Derivados de pirrol, su preparacion y su utilizacion en terapeutica.
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
MX345624B (es) Derivados 6-amido de 4,5a-epoximorfinanos para tratamiento de dolor.
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
MX2007004535A (es) Antagonistas de integrinas bifenilicos.
CY1116200T1 (el) ΠΑΡΑΓΩΓΑ ΔΙΒΕΝΖΟ[b,f][1,4]ΟΞΑΖΕΠΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΑΠΟΑΚΕΤΥΛΑΣΗΣ ΙΣΤΟΝΗΣ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal